NCT03891667View on ClinicalTrials.gov

Disulfiram: A Test of Symptom Reduction Among Patients With Previously Treated Lyme Disease

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

11

Participants

Timeline

Start Date

July 31, 2019

Primary Completion Date

November 26, 2021

Study Completion Date

March 31, 2022

Conditions
FatigueQuality of Life
Interventions
DRUG

Disulfiram

Patients will receive disulfiram for 4 weeks followed by placebo for 4 weeks or disulfiram for 8 weeks.

Trial Locations (1)

10032

Lyme Research Center New York State Psychiatric Institute, New York

All Listed Sponsors
collaborator

FDC Foundation

OTHER

lead

Research Foundation for Mental Hygiene, Inc.

OTHER

NCT03891667 - Disulfiram: A Test of Symptom Reduction Among Patients With Previously Treated Lyme Disease | Biotech Hunter | Biotech Hunter